This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Chronic Sialorrhea industry.
What is the anticipated market size of the chronic sialorrhea industry over the next few years?
The chronic sialorrhea market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, increase in population, increasing prevalence of neurological disorders, rising awareness and diagnosis, increase demand for non-invasive treatments.
The chronic sialorrhea market size is expected to see strong growth in the next few years. It will grow to $0.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing awareness about the treatment options, increasing the need for effective treatment options, growing healthcare expenditure, rising pediatric cases, and rising demand for oral gels and liquid. Major trends in the forecast period include telemedicine for remote monitoring, patient-centered care models, pharmacological innovations, integration of speech and occupational therapies, and development of long-acting pharmaceuticals.
Download Your Free Sample PDF:
What emerging drivers are expected to shape the future of the chronic sialorrhea market?
The increasing prevalence of neurodegenerative disorders is expected to propel the growth of the chronic sialorrhea market going forward. Neurodegenerative disorders refer to a group of diseases characterized by the progressive degeneration or death of nerve cells (neurons) in the brain and spinal cord. The rising neurodegenerative disorders are due to genetic factors and family history, environmental factors, better understanding of disease mechanisms, chronic health conditions, and social and psychological factors. Chronic sialorrhea is a common complication of neurodegenerative disorders like Parkinson’s disease and ALS, necessitating targeted treatments to prevent aspiration, enhance oral function, and improve patient comfort. For instance, in September 2023, according to Parkinson's UK, a UK-based charitable company, approximately 153,000 individuals in the UK are currently living with Parkinson’s, and with an aging population, this number is projected to increase by 20% to an estimated 172,000 by 2030. Therefore, the increasing prevalence of neurodegenerative disorders will drive the growth of the chronic sialorrhea market.
What emerging segments are shaping the future landscape of the chronic sialorrhea industry?
The chronic sialorrhea market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatments, Botulinum Toxin Injections, Surgical Interventions, Medical Devices And Assistive Therapies
2) By Route Of Administration: Oral Medications, Injectable Treatments, Topical Applications
3) By Patient Population: Pediatric Patients, Adult Patients
4) By End-User: Hospitals And Specialty Clinics, Rehabilitation Centers, Homecare Settings
Subsegments:
1) By Pharmacological Treatments: Anticholinergic Medications, Antidepressants, Alpha-adrenergic Agonists, Salivary Gland Modulators
2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox), Botulinum Toxin Type B (Myobloc), Localized Salivary Gland Injections
3) By Surgical Interventions: Sialendoscopy, Salivary Gland Duct Dilation or Stenting, Parotid Duct Surgery, Submandibular Gland Removal (Sialadenectomy)
4) By Medical Devices And Assistive Therapies: Oral Dryness Devices, Salivary Stimulation Devices, Lip and Mouth Exercises, Artificial Salivary Glands
View The Full Market Report:
How are emerging trends transforming the chronic sialorrhea market dynamics?
Major companies operating in the chronic sialorrhea market are focusing on developing innovative treatments, such as oral solutions, to improve patient compliance and provide non-invasive alternatives for managing chronic sialorrhea in children, enhancing safety and effectiveness while reducing side effects. An oral solution is a liquid medication formulated for oral administration, containing the active ingredient dissolved in a solvent, designed for easy ingestion. For instance, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France for the treatment of severe chronic sialorrhea in children with neurological disorders. A key feature of this product is its liquid formulation, designed for ease of administration and accurate dosing, making it particularly beneficial for pediatric patients who struggle with solid medications. It offers a well-established safety and efficacy profile, helping to improve quality of life by reducing excessive drooling, which is a common challenge in neurodevelopmental conditions like cerebral palsy.
How are key players in the chronic sialorrhea market strengthening their market position?
Major companies operating in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, Solstice Neurosciences Inc.
Which geographic areas are contributing significantly to the growth of the chronic sialorrhea sector?
North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Chronic Sialorrhea Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Chronic Sialorrhea Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment